Palisade Bio (PALI) Profit After Tax (2010 - 2026)
Palisade Bio (PALI) posted quarterly Profit After Tax of -$9.6 million for Q1 2026, down 330.49% year-over-year from $4.2 million in Q1 2025, and down 7.88% quarter-over-quarter from -$8.9 million in Q4 2025.
Palisade Bio (PALI) Profit After Tax (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Profit After Tax for 17 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 330.49% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$24.2 million (down 83.78% YoY), while the FY2025 annual figure was -$16.8 million, down 16.23% from the prior year.
- Profit After Tax retreated to -$9.6 million in Q1 2026 per PALI's latest filing, from -$8.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$2.2 million in Q1 2025 and bottomed at -$9.6 million in Q1 2026.
- Historically, Profit After Tax has averaged -$4.0 million across 5 years, with a median of -$3.5 million in 2024.
- On a YoY basis, Profit After Tax climbed as much as 92.62% in 2022 and fell as far as 446.69% in 2022.
- Palisade Bio's Profit After Tax stood at -$3.7 million in 2022, then increased by 20.13% to -$3.0 million in 2023, then retreated by 12.55% to -$3.3 million in 2024, then slumped by 166.12% to -$8.9 million in 2025, then decreased by 7.88% to -$9.6 million in 2026.
- Business Quant data shows PALI's Profit After Tax at -$9.6 million in Q1 2026, -$8.9 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | -10.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.57 Mn |
| Mar 31, 2026 | -9.60 Mn |
| Dec 31, 2025 | -8.90 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | -3.34 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -2.97 Mn |
| Sep 30, 2023 | -3.60 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.72 Mn |
| Sep 30, 2022 | -3.99 Mn |
| Jun 30, 2022 | -2.34 Mn |
| Mar 31, 2022 | -4.21 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 8.09 Mn |